Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.
Mologic would not have signed off on today's RNS if they thought there was any chance of Avacta Affimers failing clinical testing. I think it's done and they are box ticking. And I'm keeping my money where my mouth is.
End of the month will see the re-rate.......14 working days.
"The Company looks forward to providing the market with a detailed business update later this month once definitive clinical data from the lateral flow test evaluation is available."
The vaccines have raised hope, but the Cold Reality Dawns That Covid Is Likely Here to Stay
https://www.thestreet.com/mishtalk/economics/vaccines-or-not-scientists-now-believe-covid-is-here-to-stay
https://www.surescreen.com/manufacturing.
The SureScreen web site makes no mention of their manufacturing capacity.....as far as I can see. Happy to be corrected.
TEL AVIV, Israel (AP) — When it comes to fighting the coronavirus, Israel is discovering the limits of vaccines.
The country famous for its high-tech prowess and spirit of innovation is home to the world’s speediest vaccination drive, fueled from the top by national pride and a deep longing to start “getting back to life,” as Prime Minister Benjamin Netanyahu put it.
But experts say reopening the country will still take months, complicated by coronavirus mutations that have spread from Britain and South Africa, a refusal among some sectors to adhere to safety rules and wobbles in the pace of vaccinations of people under 60.
https://apnews.com/article/israel-discovers-limits-virus-vaccines-febc365b0f1ab0d794c49e4b7a1fe7f3
It gets better....we'll hear long before anything from the MHRA:
"Based on the Indonesian phase 1 clinical trial results, the company plans to conduct a further phase 2 clinical trial of the drug in Korea.
According to the revision of the Advanced Regenerative Bio Act, the health authorities can give conditional approval to drugs that have passed phase 2 clinical trials to expedite their use at hospitals fighting Covid-19. If the company manages to prove the efficacy of DWP710 in its phase 2 trials, it can speed up the treatment's launch.
?? : KBR(http://www.koreabiomed.com)
Brilliant interview (from Italy) with Pascal Soriot...the boss of AZ. Everything you want to know about the Oxford vaccine....and Europe:
https://www.repubblica.it/cronaca/2021/01/26/news/interview_pascal_soriot_ceo_astrazeneca_coronavirus_covid_vaccines-284349628/
apologies if already posted
I think it's been done and got overtaken by events. This announcement came out on 23 November and see last para:
vAvacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISIONTM platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.
Avacta is developing several coronavirus tests using Affimer binders that are highly specific to the SARS-CoV-2 virus spike protein.
The development of an Affimer-based lateral flow antigen test that can be manufactured at scale being carried out in partnership with BBI Solutions has made substantial progress. A highly scalable test device using readily available components and routine manufacturing processes has now been shown to have a sensitivity for coronavirus spike protein in laboratory samples better than 300 pg/ml which is in the range expected for spike protein in clinical samples.
In preparation for clinical validation of the lateral flow test Avacta is working on both saliva and anterior nasal swab samples. Anterior nasal swabs sample the easily accessible parts of the nose and are therefore painless and straightforward to administer, unlike nasopharyngeal swabs which are generally regarded as painful and unpleasant. Avacta and its partners will continue to develop both sampling methods in parallel in order to bring high performance COVID-19 tests to market quickly to suit a range of use cases.
The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study with COVID-19 patients of known viral load to determine the clinical sensitivity of the test. In parallel BBI Solutions is working to finalise and validate the manufacturing process so that the Group can carry out a full clinical validation on the final product to support the regulatory approval process.
Interesting address:
Trent Cottage, 1 Park Road, Alrewas, Burton-On-Trent, DE13 7AG, England
Surescreen Diagnostics
Established in 1996, SureScreen have been providing proactive, bespoke diagnostic solutions to organisations just like yours for nearly 25 years.
SureScreen looks like a wholesaler. No obvious research capability or manufacturing.
Chris Boxall of Fundamental Asset Management, an Aim specialist, told the Telegraph:
"He pointed to some of Aim’s spectacular technology-based successes such as Asos and Boohoo, the online retailers, which are worth £5.1bn and £4.6bn respectively. He said Aim’s healthcare firms had, “after many years in the wilderness”, also come to the fore during the pandemic."
hTtps://www.telegraph.co.uk/investing/shares/questor-wild-west-investing-aim-fast-maturing-grown-up-stock/